AR034284A1 - Compuestos de heterociclilalquilindol o -azaindol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la manufactura de medicamentos para tratamiento de desordenes del sistema nervioso central - Google Patents
Compuestos de heterociclilalquilindol o -azaindol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la manufactura de medicamentos para tratamiento de desordenes del sistema nervioso centralInfo
- Publication number
- AR034284A1 AR034284A1 ARP010106003A ARP010106003A AR034284A1 AR 034284 A1 AR034284 A1 AR 034284A1 AR P010106003 A ARP010106003 A AR P010106003A AR P010106003 A ARP010106003 A AR P010106003A AR 034284 A1 AR034284 A1 AR 034284A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently
- optionally substituted
- compounds
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- -1 cycloheteroalkyl Chemical group 0.000 abstract 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de heterociclilalquilindol o -azaindol, que comprenden un compuesto de la fórmula (1), en la cual: Q es SO2, CO, CONR24, CSNR25 ó CH2; W es N ó CR7; X es N ó CR9; Y es NR ó CR10R29; Z es NR21 ó CR11R30; con la condición de que cuando Y es NR entonces Z debe ser CR11R30 y con la condición adicional de que por lo menos uno de Y y Z debe ser NR ó NR21; n es 0 ó un número entero de 1 ó 2; R y R21 son cada uno independientemente, H, CNR26NR27R28, o un grupo alquilo C1-6, cicloalquilo C3-6, cicloheteroalquilo, arilo o heteroarilo cada uno opcionalmente sustituido; R1, R2 y R9 son cada uno independientemente H, halógeno, CN, OCO2R12, CO2R13, CONR22R23, CONR14NR15R16, SOmR17, NR18R19, OR20, o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloheteroalquilo, alcanoílo C1-6, arilo o heteroarilo cada uno opcionalmente sustituido; m es 0 ó un número entero de 1 ó 2; R3 y R4 son cada uno independientemente H, halógeno, alquilo C1-4 o haloalquilo C1-4, o R3 y R4 pueden tomarse conjuntamente con el átomo al cual están unidos para formar un grupo carbonilo; R5 y R6 son cada uno independientemente H o un grupo alquilo C1-6 opcionalmente sustituido; R7 es H, halógeno, o un grupo alquilo C1-6, alcoxi C1-6, arilo o heteroarilo cada uno opcionalmente sustituido; R8 es un grupo alquilo C1-6, arilo o heteroarilo opcionalmente sustituido; R10, R11, R29 y R30 son cada uno independientemente H o un grupo alquilo C1-6 opcionalmente sustituido; R12, R13 y R17 son cada uno independientemente H o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloheteroalquilo, arilo o heteroarilo opcionalmente sustituido; R14, R15, R16, R18, R19, R26, R27 y R28 son cada uno independientemente H o alquilo C1-4; R20, R22 y R23 son cada uno independientemente H o un grupo alquilo C1-6 opcionalmente sustituido; R24 y R25 son cada uno independientemente H o un grupo alquilo, arilo o heteroarilo cada uno opcionalmente sustituido; y la línea de puntos representa un enlace simple o un enlace doble; o una sal del mismo farmacéuticamente aceptable; un procedimiento para su preparación, composición farmacéutica y el uso de dichos compuestos para la manufactura de medicamentos para tratamiento de desórdenes del sistema nervioso central.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25768400P | 2000-12-22 | 2000-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034284A1 true AR034284A1 (es) | 2004-02-18 |
Family
ID=22977310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010106003A AR034284A1 (es) | 2000-12-22 | 2001-12-21 | Compuestos de heterociclilalquilindol o -azaindol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la manufactura de medicamentos para tratamiento de desordenes del sistema nervioso central |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6613781B2 (es) |
| EP (1) | EP1355900B1 (es) |
| JP (1) | JP2004520325A (es) |
| KR (1) | KR20030062440A (es) |
| CN (1) | CN1492863A (es) |
| AR (1) | AR034284A1 (es) |
| AT (1) | ATE327232T1 (es) |
| BR (1) | BR0116481A (es) |
| CA (1) | CA2432661A1 (es) |
| DE (1) | DE60119982T2 (es) |
| DK (1) | DK1355900T3 (es) |
| EA (1) | EA200300716A1 (es) |
| ES (1) | ES2264994T3 (es) |
| HU (1) | HUP0400682A2 (es) |
| IL (1) | IL156518A0 (es) |
| MX (1) | MXPA03005433A (es) |
| NO (1) | NO20032841L (es) |
| PL (1) | PL363238A1 (es) |
| WO (1) | WO2002051832A2 (es) |
| ZA (1) | ZA200305625B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4187642B2 (ja) * | 2001-06-07 | 2008-11-26 | エフ．ホフマン−ラ ロシュ アーゲー | ５−ｈｔ６受容体親和性を有する新規インドール誘導体 |
| US20030225121A1 (en) * | 2001-12-20 | 2003-12-04 | Wyeth | Heterocyclylalkylindole or-azaindole compounds as 5-hydroxytryptamine-6 ligands |
| DE60322186D1 (de) * | 2002-02-12 | 2008-08-28 | Organon Nv | 1-arylsulfonyl-3-substituierte indol und indolinederivate verwendbar zur behandlung von erkrankungen des zentralnervensystem |
| TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| EP1581492B1 (en) * | 2002-11-28 | 2008-07-16 | Suven Life Sciences Limited | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them |
| BRPI0406883A (pt) * | 2003-01-22 | 2006-01-03 | Lilly Co Eli | Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto |
| BRPI0407253A (pt) * | 2003-02-14 | 2006-01-31 | Wyeth Corp | Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos |
| AU2004213375A1 (en) * | 2003-02-14 | 2004-09-02 | Wyeth | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-Hydroxytryptamine-6 ligands |
| ES2222828B1 (es) | 2003-07-30 | 2006-04-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos. |
| CA2532382A1 (en) * | 2003-07-31 | 2005-02-10 | Wyeth | N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands |
| EA013875B1 (ru) * | 2005-08-12 | 2010-08-30 | Сувен Лайф Сайенсиз Лимитед | Аминоарильные сульфонамидные производные как функциональные 5-нтлиганды |
| NZ565872A (en) * | 2005-08-15 | 2011-06-30 | Wyeth Corp | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands |
| US7915286B2 (en) | 2005-09-16 | 2011-03-29 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
| EP1842541A1 (en) * | 2006-03-29 | 2007-10-10 | G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg | Plant components and extracts and uses thereof |
| EP2001865A1 (en) * | 2006-04-05 | 2008-12-17 | Wyeth a Corporation of the State of Delaware | Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands |
| WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
| SI2124944T1 (sl) | 2007-03-14 | 2012-05-31 | Ranbaxy Lab Ltd | Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze |
| KR20100031578A (ko) * | 2007-05-24 | 2010-03-23 | 메모리 파마슈티칼스 코포레이션 | 5-ｈｔ6 수용체 친화성을 갖는 4'-치환된 화합물 |
| US20100016297A1 (en) * | 2008-06-24 | 2010-01-21 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| US20100022581A1 (en) * | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| US20100029629A1 (en) * | 2008-07-25 | 2010-02-04 | Memory Pharmaceuticals Corporation | Acyclic compounds having 5-ht6 receptor affinity |
| US20100056531A1 (en) * | 2008-08-22 | 2010-03-04 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| CN104725295B (zh) | 2013-12-20 | 2019-05-24 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
| CA2953004C (en) | 2014-07-08 | 2023-02-21 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208417A (en) | 1978-06-29 | 1980-06-17 | Pharmindustrie | Indole derivatives and their use as anxiolytics |
| FR2701026B1 (fr) | 1993-02-02 | 1995-03-31 | Adir | Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| IT1271352B (it) | 1993-04-08 | 1997-05-27 | Boehringer Ingelheim Italia | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale |
| US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| US6133287A (en) * | 1998-03-24 | 2000-10-17 | Allelix Biopharmaceuticals Inc. | Piperidine-indole compounds having 5-HT6 affinity |
| EP1076658A1 (en) * | 1998-04-29 | 2001-02-21 | American Home Products Corporation | Serotonergic agents |
| US6251893B1 (en) | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
| US6066637A (en) | 1998-06-19 | 2000-05-23 | American Home Products Corporation | Indolyl derivatives as serotonergic agents |
| US6191141B1 (en) | 1999-08-12 | 2001-02-20 | Nps Allelix Corp. | Azaindoles having serotonin receptor affinity |
| KR100823908B1 (ko) * | 2000-10-20 | 2008-04-21 | 바이오비트럼 에이비(피유비엘) | 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도 |
-
2001
- 2001-12-11 MX MXPA03005433A patent/MXPA03005433A/es active IP Right Grant
- 2001-12-11 EP EP01993251A patent/EP1355900B1/en not_active Expired - Lifetime
- 2001-12-11 PL PL01363238A patent/PL363238A1/xx unknown
- 2001-12-11 DK DK01993251T patent/DK1355900T3/da active
- 2001-12-11 BR BR0116481-3A patent/BR0116481A/pt not_active IP Right Cessation
- 2001-12-11 EA EA200300716A patent/EA200300716A1/ru unknown
- 2001-12-11 ES ES01993251T patent/ES2264994T3/es not_active Expired - Lifetime
- 2001-12-11 CN CNA018228232A patent/CN1492863A/zh active Pending
- 2001-12-11 AT AT01993251T patent/ATE327232T1/de not_active IP Right Cessation
- 2001-12-11 DE DE60119982T patent/DE60119982T2/de not_active Expired - Fee Related
- 2001-12-11 WO PCT/US2001/047938 patent/WO2002051832A2/en not_active Ceased
- 2001-12-11 CA CA002432661A patent/CA2432661A1/en not_active Abandoned
- 2001-12-11 HU HU0400682A patent/HUP0400682A2/hu unknown
- 2001-12-11 KR KR10-2003-7008333A patent/KR20030062440A/ko not_active Withdrawn
- 2001-12-11 JP JP2002552927A patent/JP2004520325A/ja active Pending
- 2001-12-11 IL IL15651801A patent/IL156518A0/xx unknown
- 2001-12-20 US US10/028,487 patent/US6613781B2/en not_active Expired - Fee Related
- 2001-12-21 AR ARP010106003A patent/AR034284A1/es unknown
-
2003
- 2003-06-20 NO NO20032841A patent/NO20032841L/no not_active Application Discontinuation
- 2003-07-21 ZA ZA200305625A patent/ZA200305625B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20032841D0 (no) | 2003-06-20 |
| WO2002051832A2 (en) | 2002-07-04 |
| ES2264994T3 (es) | 2007-02-01 |
| DK1355900T3 (da) | 2006-09-11 |
| IL156518A0 (en) | 2004-01-04 |
| ZA200305625B (en) | 2004-10-21 |
| US6613781B2 (en) | 2003-09-02 |
| CN1492863A (zh) | 2004-04-28 |
| JP2004520325A (ja) | 2004-07-08 |
| EP1355900A2 (en) | 2003-10-29 |
| NO20032841L (no) | 2003-08-20 |
| BR0116481A (pt) | 2004-01-06 |
| PL363238A1 (en) | 2004-11-15 |
| US20020128477A1 (en) | 2002-09-12 |
| DE60119982T2 (de) | 2006-12-21 |
| WO2002051832A3 (en) | 2002-09-06 |
| MXPA03005433A (es) | 2003-09-10 |
| EP1355900B1 (en) | 2006-05-24 |
| DE60119982D1 (de) | 2006-06-29 |
| KR20030062440A (ko) | 2003-07-25 |
| HUP0400682A2 (hu) | 2004-06-28 |
| EA200300716A1 (ru) | 2003-12-25 |
| CA2432661A1 (en) | 2002-07-04 |
| ATE327232T1 (de) | 2006-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR034284A1 (es) | Compuestos de heterociclilalquilindol o -azaindol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la manufactura de medicamentos para tratamiento de desordenes del sistema nervioso central | |
| AR034283A1 (es) | Compuestos heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
| AR054809A1 (es) | Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| AR035325A1 (es) | Derivados de adamantano, un proceso para su preparacion, composicion farmaceutica, un proceso para la preparacion de dicha composicion, y el uso de dichos derivados para la fabricacion de un medicamento | |
| AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
| AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
| AR074822A1 (es) | Compuestos heterociclicos de pirazina utiles como inhibidores de proteinquinasas atr, composiciones farmaceuticas que los comprenden y uso de los mismos en el tratamiento del cancer | |
| AR034270A1 (es) | 1-aril- o 1-alquilsulfonil-heterociclilbenzazoles como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento | |
| AR030053A1 (es) | 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas | |
| DK256890A (da) | Benzo-piperidin-, -piperidyliden- og piperazinforbindelser, kompositioner indeholdende forbindelserne og fremgangsmaader til forbindelsernes fremstilling og anvendelse | |
| AR048302A1 (es) | DERIVADOS DE PIRAZOLO-PIRIMIDINA, DE PIRAZOLO-PIRIMIDINONA, DE PIRAZOLO-PIRIDINA Y DE PIRAZOLO-PIRAZINA FUSIONADOS, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA PREPARACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA CINASA P38 | |
| AR043181A1 (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxiptamina-6 | |
| AR037906A1 (es) | Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR035812A1 (es) | Compuestos de acrilamida farmaceuticamente efectivos como inhibidores de la enoil-acp reductasa-fabi-; composiciones formuladas con dichos compuestos, metodo para inhibir dicha reductasa , respectivamente, para tratar infecciones bacterianas utilizando dichos compuestos y uso de los compuestos menci | |
| AR043875A1 (es) | Derivados de quinazolina, proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| ES2566973T9 (es) | Uso de SNS-595 para tratar leucemia | |
| AR057915A1 (es) | Compuesto con estructura de cinamida de dos ciclos con actividad inhibitoria de la produccion de abeta40 y abeta42, un agente farmaceutico que lo comprende y el uso de este en el tratamiento de enfermedades mentales y neurodegenerativas. | |
| AR034588A1 (es) | Derivados heterociclilalcoxi-, -alquiltio- y -alquilamino-benzazol como ligandos de 5-hidroxitriptamina-6, un proceso para su preparacion, intermediarios, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos | |
| AR026487A1 (es) | Derivados de espiro[2h-1-benzopiran-2,4'-piperidina] para el uso en terapia, especificamente para el tratamiento de alteraciones del snc | |
| ATE277062T1 (de) | Neue makrolidderivate | |
| ES2123546T3 (es) | Uso de derivados de 1-(aminoalquil)-3-quinoxalina-2-ona para la preparacion de composiciones neuroprotectoras. | |
| ES2090024T3 (es) | Compuestos de cefemo y procedimientos para su preparacion. | |
| AR046446A1 (es) | Compuestos de sulfoniltetrahidro-3h-benzo(e)indol-8-amina como ligandos de la 5-hidroxitriptamina-6 (5-ht6), metodos para su preparacion y composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |